Quick Answer
Maze Therapeutics, Inc. reported Cash and Equivalents of $189.25 million for fiscal year 2025.
Maze Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $189.25M | -3.8% |
| 2024 | $196.81M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $316.77M | +111.7% | +19.7% |
| June 30, 2025 | $264.54M | +51.1% | -10.1% |
| March 31, 2025 | $294.37M | +880.5% | +49.6% |
| December 31, 2024 | $196.81M | — | +31.6% |
| September 30, 2024 | $149.61M | — | -14.5% |
| June 30, 2024 | $175.06M | — | +483.1% |
| March 31, 2024 | $30.02M | — | — |
- Maze Therapeutics, Inc. showed a decrease of -3.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, Maze Therapeutics, Inc.’s cash and equivalents has declined by 3.8% (from $196.81 million to $189.25 million).
- The most recent figure is from Maze Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: